Stay updated with breaking news from Infection Intel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Staying Ahead with Company Updates and Product Innovations. Read the news from PerfectClean, the FDA, and the CDC.
Merck's V116, a 21-valent pneumococcal vaccine, exhibits strong immunogenicity and coverage in diverse adult populations. Real-world data reveal its potential to combat pneumococcal diseases effectively.
Explore Agilent Technologies' role in advancing infectious disease research through cutting-edge solutions, from in vitro transcribed RNA vaccine testing to biofilm evaluation.
Learn about FendX Technologies' breakthrough nanotechnology, including REPELWRAP film and a spray formulation, designed to prevent the spread of infectious diseases on various surfaces.
Discover how Merck's V116 vaccine, now under FDA priority review, addresses invasive pneumococcal disease in adults, bridging critical protection gaps with 8 unique serotypes.